Navigation Links
Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA

A new drug treatment, Revlimid for treatment of myelodysplastic syndrome (MDS), a rare blood disorder has been approved by the Food and Drug Administration (FDA). The approval was announced by Celgene Corp, manufacturer of the drug.//

The exact cause of MDS is not known. However, increased incidence of MDS has been noticed following radiotherapy or chemotherapy. Transfusion of blood and blood products (platelet) is the usual form of treatment. Anti-biotics may also be given to treat the associated infection.

Symptoms of MDS include fatigue, generalized weakness, susceptibility to infections, bleeding tendency and fever. The incidence of MDS is as high as 7000 to 12000 in the United States with a majority of the cases diagnosed in patients over 60 years.

The new drug has been approved by the FDA, owing to its improved performance in clinical trials. The need for a blood transfusion was eliminated in patients treated with Revlimid. Infact, following 3 months of therapy, a majority of the patients became independent of transfusions. This effect was observed for an average of 44 weeks.

The new drug closely resembles another drug, Thalomid, known to cause severe birth defects when administered to the pregnant mother. On account of this structural similarity, a ‘black box’ warning would be issued to prevent fetal exposure to Revlimid.

The drug would further be marketed under a strict adherence to a risk-management strategy, called RevAssist. According to the plan, only registered participants of the program (doctors and pharmacists) would be authorized to prescribe or market Revlimid. This is expected to reduce the probability of fetal exposure to the teratogenic drug.


'"/>




Page: 1

Related medicine news :

1. Revlimid Approved By FDA For Multiple Myeloma
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. New FDA Approved Drug To Treat Migraine
4. New FDA Approved Drug NATRECOR For Heart Failure Patients
5. New Oral Rinse For Gingivitis Approved By FDA
6. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
7. AIDS Generic Drugs Approved by FDA for Sale in US
8. FDA Approved Nerve-Stimulation Therapy Now Available In New York
9. Pfizer’s Eraxis Approved By The FD
10. Inhalers for Kids Was Approved By the FDA
11. Alcoholism Drug Vivitrol Approved By FDA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: